Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Obsessive-Compulsive Disorder, Anxiety D...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Genetic variants in SSRI metabolism (4 years)
  • Behavioural Disinhibition (4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-01-02
Completion: 2026-12-30
Eligibility
Age: 6 Years – 17 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Calgary
Collaborators: Hotchkiss Brain Institute, University of Calgary, Alberta Health services
Principal Investigators:
  • Chad Bousman, PhD (PRINCIPAL_INVESTIGATOR) - University of Calgary
  • Paul Arnold, MD (PRINCIPAL_INVESTIGATOR) - University of Calgary
Contact Information
Study Contact:
Madison Heintz, MSW
5875739747
psychpgxlab@ucalgary.ca
Abdullah Al Maruf, PhD
abdullahal.maruf@ucalgary.ca
Madison Heintz, MSW
Child and Adolescent Addiction, Mental Health & Psychiatry
Interventions
N/A
Study Locations (1 sites)
Child and Adolescent Addiction, Mental Health & Psychiatry, Calgary, Alberta Canada
Eligibility Criteria
Inclusion Criteria: 1. Aged 6 - 24 years 2. Medical records available 3. Diagnosis of MDD, anxiety disorder, or OCD 4. Current or past history of SSRI therapy Exclusion Criteria: 1. Inability of parent/legal guardian to give informed consent 2. Inability of the child to give informed assent 3. Unwillingness of child to provide saliva sample for genetic analysis 4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.
Conditions Depression
Phase Not Applicable
Enrollment 36
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Intermittent theta-burst stimulation (iTBS), a variant of repetitive transcranial magnetic stimulation (rTMS), is a well-documented treatment for depression. The aim of this study is to evaluate the effectiveness of an accelerated iTBS protocol (1W-AiTBS) in routine clinical practice. In the accelerated protocol, patients receive 600 pulses per session, for a total of 30 sessions administered over 5-14 treatment days. Patient inclusion will take place over a maximum period of 1.5 years, with a maximum sample size of 150 patients. The target sample size is at least 36 patients. Patients will complete self-rating questionnaires at screening, before and after treatment, and at 6 weeks, 12 weeks, and 6 months from the first day of treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: iTBS (intermittent theta-burst stimulation) — The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.

Primary Outcomes

  • Difference in MADRS-S from baseline to six weeks after first iTBS treatment (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-01
Completion: 2027-03-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Contact Information
Study Contact:
Melker Hagsäter, MD, MSc, PhD, PhD
+46 3039 8000
melker.hagsater@vgregion.se
Caroline Wass
+46 3039 8000
caroline.wass@vgregion.se
Sahlgrenska University Hospital
Melker Hagsäter
+46 10441 00 00
melker.hagsater@vgregion.se
Kungälv Hospital, Kungälv
Interventions
  • Device: iTBS (intermittent theta-burst stimulation) — The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil. The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Study Locations (3 sites)
Sahlgrenska University Hospital, Gothenburg, Sweden
Kungälv Hospital, Kungälv, Kungälv, Sweden
Central Hospital Växjö, Vaxjo, Sweden
Eligibility Criteria
Inclusion Criteria: * diagnosis of depression verified through a Mini International Neuropsychiatric Interview (M.I.N.I.) * provision of signed informed consent form * indication for TMS is depression Exclusion Criteria: * conductive ferromagnetic or other metals implanted in the head or within 30 cm of the treatment coil * implanted device that is activated or controlled in any way by physiological signals * implanted mediation pumps * intracardiac lines, even when removed * any condition that seriously increases the risk of non-compliance or loss of follow-up
Conditions Depression, Anxiety, Methamphetamine Dep...
Phase PHASE3
Enrollment 29
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Creatine monohydrate

Primary Outcomes

  • Hamilton Depression Rating Scale (HAMD) Scores (This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation).)
  • Hamilton Anxiety Rating Scale (HAMA) Scores (This data will be assessed after 12 participants have completed the study and again after a completed sample size of 24 is achieved. The data will be presented at study completion (anticipated: 12 months after study initiation).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2015-11
Completion: 2017-05
Eligibility
Age: 18 Years – 59 Years
Sex: ALL
Volunteers: false
Enrollment: 29 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Montana State University
Principal Investigators:
  • Tracy Hellem, PhD (PRINCIPAL_INVESTIGATOR) - Montana State University
Contact Information
Study Contact:
Tracy Hellem, PhD
406 243 2110
tracy.hellem1@montana.edu
Tracy Hellem, PhD
406-243-2110
tracy.Hellem1@montana.edu
Montana State University College of Nursing (Missoula campus)
4062432110
Montana State University College of Nursing (Missoula campus)
Interventions
  • Drug: Creatine monohydrate
Study Locations (1 sites)
Montana State University College of Nursing (Missoula campus), Missoula, Montana 59812 United States
Eligibility Criteria
Inclusion Criteria: * Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse * Current diagnosis of major depressive disorder (primary or substance-induced) * Current diagnosis of an anxiety disorder (primary or substance-induced) * Current Hamilton Depression Rating scale score \> or = to 16 * Current Hamilton Anxiety Scale score \> = to 18 * If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation Exclusion Criteria: * Persons unable to provide adequate informed consent * Persons who are at clinically significant suicidal or homicidal risk * Primary substance-related diagnosis other than methamphetamine dependence or abuse * Positive pregnancy test (females only) * History of renal disease * Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing * History of hypersensitivity reaction to creatine
Conditions Sleep, Postpartum Depression, Pregnancy ...
Phase NA
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Insufficient and disrupted sleep are rarely addressed in expectant and new mothers, despite evidence that disturbed sleep is a modifiable risk factor for negative health outcomes for mothers and their children. In this study the investigators will adapt, refine, and pilot test the implementation of a behavioral sleep intervention consisting of short videos designed to accompany a free behavioral sleep app. In Phase 1, the investigators will develop and refine the intervention with input from direct care workers who serve at-risk perinatal women. In Phase 2, direct care workers will deploy the training to expectant mothers with sleep concerns and the investigators will assess the reach, effectiveness, adoption, implementation, and maintenance of this scalable, efficient intervention to improve sleep.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Education about behavioral strategies to improve sleep — In collaboration with direct care workers, the investigators are developing an intervention to help home visitors support clients who experience sleep difficulties in the perinatal period. The intervention consists of a series of educational videos about promoting healthy sleep and addressing sleep difficulties during pregnancy and the postpartum period.

Primary Outcomes

  • Phase 1 Reach (Throughout training period, i.e., for about 6 months; one time measure.)
  • Phase 1 Effectiveness (At enrollment and 1 month after training.)
  • Phase 1 Acceptability (1 month after training)
  • Phase 2 Reach (one time measure during enrollment period, ~ 6 months)
  • Phase 2 Effectiveness (6 weeks after enrollment)
  • Phase 2 Effectiveness - Insomnia Severity Index (at enrollment and 6 weeks after enrollment)
  • Phase 2 Effectiveness - Implementation (from enrolllment through 6 weeks after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-08
Completion: 2025-06-30
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rhode Island Hospital
Collaborators: Bradley Hospital
Principal Investigators:
  • Katherine M Sharkey, MD, PhD (PRINCIPAL_INVESTIGATOR) - Rhode Island Hospital
Contact Information
Study Contact:
Katherine M Sharkey, MD, PhD
401-793-3497
katherine_sharkey@brown.edu
Katherine M Sharkey, MD, PhD
401-793-3497
katherine_sharkey@brown.edu
Rhode Island Hospital
Interventions
  • Behavioral: Education about behavioral strategies to improve sleep — In collaboration with direct care workers, the investigators are developing an intervention to help home visitors support clients who experience sleep difficulties in the perinatal period. The intervention consists of a series of educational videos about promoting healthy sleep and addressing sleep difficulties during pregnancy and the postpartum period.
Study Locations (1 sites)
Rhode Island Hospital, Providence, Rhode Island 02903 United States
Eligibility Criteria
Phase 1 Inclusion Criteria: To qualify for Phase 1 enrollment, participants must be: * over 18 years of age; * working with expectant and new mothers in a community setting (i.e., outpatient clinic, social service agency, home visiting program, community center); * in a role where they would be expected to meet with the same client on at least 4 occasions during the perinatal period; in situations where a team-based approach is used to provide services and a client may not see the exact same person at each visit, team members will qualify if they all enroll in the study (e.g., two nurse midwives who provide coverage for each other may both enroll); * have access to a smart phone to view the training videos, complete the assessments, and access the free CBTi Coach app; speak and read English or Spanish; * express interest in providing their clients with additional tools to manage sleep disturbances in pregnancy and the postpartum period. Phase 1 Exclusion Criteria: The investigators will exclude potential participants who: * already have certification or a specialty in perinatal sleep (e.g., therapists with formal training in CBTi, individuals with sleep coaching practices); * those who do not have longitudinal relationships with clients (e.g., intake workers). Phase 2 Inclusion Criteria: To qualify, Phase 2 participants must be: * expectant parents OR new parents up to 1 year postpartum; * age 18 to 45 years old; * receiving community-based health, well-being, and or mental health services or treatment from individuals who participated in Phase 1; * speak and read English or Spanish; * have access to a smart phone to view the training videos and complete the assessments; * have clinically significant sleep difficulties defined as an Insomnia Severity Index score greater than 7. Phase 2 Exclusion Criteria: The investigators will exclude potential participants whose infants will not be living in the home or who will have a nighttime caregiver.
Conditions Treatment Resistant Depression, MDD, Maj...
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Psilocybin — A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
  • Device: Accelerated intermittent theta burst (aiTBS) rTMS treatment — A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
  • Drug: Low-dose psilocybin — A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
  • Device: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment — The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.

Primary Outcomes

  • Montgomery Asberg Depression Rating Scale (MADRS) (12 months)
  • fMRI task-evoked brain activation (At both 1 week and 2 weeks)
  • fMRI resting state (At both 1 week and 2 weeks)
  • EEG functional connectivity change (At both 1 week and 2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-10
Completion: 2030-12-31
Eligibility
Age: 22 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Texas at Austin
Principal Investigators:
  • Gregory A Fonzo, Ph.D. (PRINCIPAL_INVESTIGATOR) - The University of Texas at Austin
Contact Information
Study Contact:
Lauren K Enten, B.S.A.
512-495-5856
psychedelics@utexas.edu
Gregory A Fonzo, Ph.D.
fonzolab@austin.utexas.edu
Lauren Enten, B.S.A.
512-495-5856
fonzolab@austin.utexas.edu
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600
Interventions
  • Drug: Psilocybin — A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (COMP360).
  • Device: Accelerated intermittent theta burst (aiTBS) rTMS treatment — A form of non-invasive brain stimulation that delivers a series of quick magnetic pulses to the scalp and a portion of the brain. It will be targeted to a functional magnetic resonance imaging (fMRI) functional connectivity-guided personalized left dorsolateral prefrontal cortex target using neuronavigation and delivered over 10 sessions daily for 5 consecutive days at 90% of coil-to-target depth-corrected resting motor threshold.
  • Drug: Low-dose psilocybin — A psychedelic drug found in certain mushrooms. It will be in a low-dose form of the experimental dose as a 1mg capsule of psilocybin (COMP360).
  • Device: Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment — The sham version is meant to look and feel like the active SAINT rTMS, but the main difference is that the brain is not being stimulated like the active condition.
Study Locations (1 sites)
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas 78712 United States
Eligibility Criteria
Inclusion Criteria: 1. Adults, ages 22-65. 2. English language comprehension suitable to understand experimenter instructions and to communicate to study personnel/staff reasonably easily. 3. Current major depressive episode (without psychotic features), either as part of recurrent major depressive disorder (MDD) or single episode MDD with current episode present for at least the past 3 months (as determined by the Structured Clinical Interview for DSM-5; SCID-5). 4. Montgomery Asberg Depression Rating Scale (MADRS) score of 20 or greater at baseline assessment (at least moderate severity). 5. 1\. Treatment-resistant MDD, defined as either: a) failure to respond to an adequate dose and duration of two or more pharmacological treatments, with at least one failed medication trial occurring in the current major depressive episode; or b) failure to respond to an adequate dose and duration of 2 or more pharmacological treatments of different pharmacological classes in one or more past major depressive episodes. Adequate treatment dose and duration will be determined through the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ). Augmentation, where an add-on medication is used, will be counted as a second treatment, provided it is approved as an adjunctive treatment of MDD in the country where prescribed. 6. Willingness and ability to attend daily, full-day visits to the research site for a period of \~2 weeks and to participate in all study procedures (clinical assessments, treatments, and neurobiological assessments). 7. If currently taking an antidepressant medication (an SSRI, SNRI, or atypical antidepressant), antipsychotic, and/or other augmenting medication (e.g., lithium), willingness to discontinue medication(s) over a 2-8 week period with the assistance of study staff and maintain at least a 2-5 week period (5-week period for fluoxetine) off of medications prior to the baseline visit AND willingness to remain off medications for a period of 1 month following the end of the treatment course (approximately 6-8 weeks after the baseline visit). Exclusion Criteria: 1. Prior history or current diagnosis of a psychotic disorder (including MDD with psychotic features), bipolar disorder, or personality disorder (based on medical history, clinician judgement, SCID-5 and/or SCID for Personality Disorders). 2. Current diagnosis of posttraumatic stress disorder, acute stress disorder, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, or alcohol or substance-use disorder. 3. Having met criteria for an alcohol or substance-use disorder within the past year. 4. Use of electroconvulsive therapy, deep brain stimulation, or vagus nerve stimulation during the current major depressive episode. 5. Any prior rTMS treatment (10Hz, 5Hz, 1Hz, or conventional intermittent theta burst). 6. Current participation in an evidence-based psychotherapy for major depression (e.g., cognitive behavioral therapy, behavioral activation). Ongoing supportive psychotherapy is allowable if maintained at the same frequency throughout the duration of the short-term follow-up clinical endpoint (1 month after treatment cessation) of the study and if no recent change in therapy type or frequency for 1 month prior to enrollment. 7. Exhibiting significant suicide risk within the past 12 months, at screening, or at baseline, as evidenced by: a) suicidal ideation with some intent to act but no specific plan (item #4 from the Columbia Suicide Severity Rating Scale57; C-SSRS); b) suicidal ideation with intent to act and a specific plan (item #5 from the C-SSRS); c) suicide attempt or non-suicidal self-injury requiring medical attention in the past 12 months; or d) self-report of significant suicidal ideation with intent or significant non-suicidal self-injury during screening or baseline clinical interview. 8. Major depressive episode that is secondary to a medication or a general medical condition, as judged by investigators. 9. Any other factors, such as major medical conditions, unstable housing or threatening life circumstances, erratic behavior, etc. that are judged by the investigators to be a significant barrier to participation in the study protocol and/or to establishing therapeutic rapport necessary for safe administration of psilocybin. 10. Prior past-year ingestion of a serotonergic psychedelic, e.g., psilocybin, LSD, mescaline, dimethyltryptamine, etc. or more than 5 lifetime ingestions of a serotonergic psychedelic on separate occasions. 11. Participant unwillingness to not ingest or use additional serotonergic psychedelics outside the context of study procedures for the duration of the study follow-up period (12 months). 12. Ferrous metal, metallic implants, or implanted medical devices that would preclude administration of rTMS and/or participation in MRI procedures, including but not limited to: cochlear implants, implanted brain stimulators, aneurysm clips. 13. Past history of seizures or epilepsy (rTMS risk). 14. Neurological disorder, including epilepsy, stroke, or history of brain surgery. 15. Past penetrating brain injury or any head injury resulting in a loss of consciousness for 30 minutes or more or post-concussive symptoms for more than seven days following a head injury. 16. Head injury in the past two months, regardless of severity. 17. Currently pregnant and/or nursing or about to become pregnant. A positive urine pregnancy test at screening and/or baseline will lead to participant exclusion from the study. 18. Engagement in sexual intercourse which could result in pregnancy without use of a highly effective contraceptive method throughout participation in the study and for at least three months after COMP360 (psilocybin) administration. 19. Severe claustrophobia (prohibiting MRI acquisition). 20. Uncontrolled hypertension (resting blood pressure \> 140/90 mm hg). 21. Uncontrolled thyroid disease as indicated by unstable thyroid hormone dosage \< 3 months prior to screening, or abnormal and clinically significant thyroxine (FT4) levels (a free FT4 measurement will be conducted for all participants with an out-of-range thyroid-stimulating hormone \[TSH\] value irrespective of thyroid history). 22. Lifetime history of cardiomyopathy, stroke, heart disease, heart attack, tachycardia, elongated QT-interval corrected by Friderichia (\> 450ms for men and \> 470ms for women); clinically significant cardiac arrhythmia within 1 year of study entry; and/or abnormal electrocardiogram on study entry. 23. Type I diabetes mellitus or uncontrolled Type II diabetes mellitus (defined by hemoglobin A1c \> 8% at screening) or a history of diabetic ketoacidosis, hyperglycemic coma, or severe hypoglycemia with loss of consciousness (\< 3 months prior to signing of consent form). 24. Positive urine drug screening for drugs of abuse at screening and/or baseline will trigger a review with participant and assessment for eligibility based on pattern of use and willingness to abstain in conjunction with medical monitor and investigative team. 25. Clinically-significant results from physical examination, blood test, urine test, vital signs, or ECG at screening and/or baseline. 26. Current enrollment in another interventional study or participation within such a study within 6 months of screening. 27. Self-reported hypersensitivity to psilocybin or another serotonergic psychedelic.
Conditions Anhedonia
Phase NA
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to investigate whether transcranial direct-current stimulation (tDCS) will engage reward-related brain circuitry, more specifically the uncinate fasciculus (UF) tract, which connects the orbitofrontal cortex (OFC) and nucleus accumbens (NAcc) regions. Also to evaluate whether the changes in the fractional anisotropy (FA) of the UF tract are associated with changes of clinical symptoms of anhedonia and finally to investigate the moderation role of simulated electric fields (EFs) in an association between FA of the UF and symptoms of anhedonia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: active tDCS — Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
  • Device: sham tDCS — Subjects will receive a dose from a "sham-tDCS"that is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later

Primary Outcomes

  • change in the fractional anisotropy of the uncinate fasciculus (baseline, 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-10-06
Completion: 2026-12-01
Eligibility
Age: 18 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: Milken Institute
Principal Investigators:
  • Jair C Soares, MD,PhD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Jair C Soares, MD,PhD
(713) 486-6663
UTMoodDisorders@uth.tmc.edu
Alexandre P Diaz, MD,PhD
(713) 486-6663
UTMoodDisorders@uth.tmc.edu
Jair C Soares, MD,PhD
(713) 486-6663
UTMoodDisorders@uth.tmc.edu
The University of Texas Health Science Center at Houston
Interventions
  • Device: active tDCS — Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
  • Device: sham tDCS — Subjects will receive a dose from a "sham-tDCS"that is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
Study Locations (1 sites)
The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * diagnosis of Bipolar Disorder and clinically significant anhedonia * mild symptoms of depression Exclusion Criteria: * substance abuse/dependence and any use of drugs (except alcohol or nicotine) in the previous month of the baseline assessment * participants with personality disorder that would interfere with study participation according to clinical judgment * previous neurological conditions (epilepsy, traumatic brain injury, stroke, etc) * any severe, life-threatening non-psychiatric medical condition * specific contraindications for tDCS (metallic plates in the head) * Participants identified as acutely suicidal or severely agitated
Conditions Depression Moderate, Anxiety, Social, Pa...
Phase Not Applicable
Enrollment 800
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational multicentre study is to address the effectiveness and cost-effectiveness of providing a therapist guided internet based cognitive behavioural therapy (ICBT) for common mental disorders in a routine healthcare setting. Main research questions is 1) What is the effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics in routine care? 2) What is the cost-effectiveness of guided internet based treatment for moderate depression, panic disorder and social anxiety disorder across clinics? 3) Who benefits from guided internet-delivered treatment? 4) What are the predictors of drop-out from guided internet based treatment? 5) To what extent does user experiences of guided internet based treatment influence adherence and effectiveness? Participants will receive up to nine guided ICBT sessions (modules) and answer questionnaires covering symptoms severity, health related quality of life, work and social ability, user satisfaction and medication. All questionnaires are part of the standard patient follow up routines in the four treatment locations participating in the study. Analytical approach is to compare locations/clinics and subgroups of patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: eMeistring — Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit

Primary Outcomes

  • Depression severity (Pre treatment (T1), up to 14 weeks after treatment start (T2), six months after T2 (T3) and after two years (T4))
  • Social phobia (Pre treatment (T1), up to 14 weeks after treatment start (T2), six months after T2 (T3) and after two years (T4))
  • Panic disorder symptoms (Pre treatment (T1), up to 14 weeks after treatment start (T2), six months after T2 (T3) and after two years (T4))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-09-09
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: St. Olavs Hospital
Collaborators: Haukeland University Hospital, The Hospital of Vestfold, Sykehuset Innlandet HF
Principal Investigators:
  • Elin T Ulleberg, Master (PRINCIPAL_INVESTIGATOR) - St. Olavs Hospital
Contact Information
Study Contact:
Vidar Halsteinli, PhD
+4793021081
vidar.halsteinli@stolav.no
Jørn Heggelund, PhD
+4792409017
jorn.heggelund@stolav.no
Tine Nordgreen, PhD
+4790094913
tine.nordgreen@helse-bergen.no
Helse Bergen HF
Interventions
  • Behavioral: eMeistring — Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
Study Locations (4 sites)
Helse Bergen HF, Bergen, Norway
Sykehuset Innlandet HF, Lillehammer, Norway
St. Olavs Hospital HF, Trondheim, Norway
Sykehuset i Vestfold HF, Tønsberg, Norway
Eligibility Criteria
Inclusion Criteria: Having moderate depression, panic disorder and social anxiety disorder as a primary disorder. Access to computer and internet. Exclusion Criteria: Having severe depression, suicidal impulses and thoughts, bipolar disorders, psychosis, substance abuse, unstable medication last month, severe reading or writing disabilities.
Conditions Depression, Depressive Disorder, Major
Phase NA
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Repetitive transcranial magnetic stimulation (rTMS) is a Health Canada approved treatment for major depression. Theta burst stimulation (TBS), a type of rTMS, is a very promising new treatment for major depression in adults and adolescents. However, very few studies have assessed the efficacy of accelerated, three times a day TBS in comparison with standard once a day TBS in adolescents. The study aims to explore further evidence in hopes to conduct a large-scale, randomized, multisite, placebo-controlled clinical trial evaluating the effects of a functional magnetic resonance imaging (fMRI)-guided accelerated rTMS protocol vs. standard once/daily rTMS for treatment-resistant depression in adolescents.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Theta Burst Stimulation — Cool B70 coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Primary Outcomes

  • Compare the efficacy of accelerated intermittent theta burst stimulation (iTBS) and standard once daily iTBS on clinical response in adolescents. (Administered at screening, weekly for 2 weeks in accelerated group, every 3rd week for 6 weeks in once/daily (standard) group, as well as 2-, 4- and 12-weeks post-treatment course for both treatment protocols.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2027-08-01
Eligibility
Age: 16 Years – 19 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Royal Ottawa Mental Health Centre
Collaborators: Université de Sherbrooke
Principal Investigators:
  • Sara Tremblay, PhD (PRINCIPAL_INVESTIGATOR) - The Royal's Institute of Mental Health Research
  • Jean-François Lepage, PhD (PRINCIPAL_INVESTIGATOR) - Sherbrooke University
Contact Information
Study Contact:
Stacey Shim, MSc
613-722-6521
stacey.shim@theroyal.ca
Maya El-Outa, BSc
613-722-6521
Maya.El-Outa@theroyal.ca
Sara Tremblay, PhD
613-722-6521
Sara.Tremblay@theroyal.ca
The Royal's Institute of Mental Health Research
Interventions
  • Device: Theta Burst Stimulation — Cool B70 coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
Study Locations (1 sites)
The Royal's Institute of Mental Health Research, Ottawa, Ontario K1Z 7K4 Canada
Eligibility Criteria
Inclusion Criteria: 1. Voluntary and competent to consent. 2. Ages 16-19 years old. 3. Can speak and read English. 4. Primary and/or predominant diagnosis of major depressive episode without psychotic features in the current episode, confirmed by The Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). 5. Depressive symptoms have not improved after ≥ 1 adequate dose of antidepressant in the current depressive episode. 6. Moderate symptoms in the current depressive episode, indexed by a score of at least 40 on the Children's Depression Rating Scale Revised for depression (CDRS-R). 7. Are able to adhere to the treatment schedule. 8. Have stable psychotropic medications and/or psychotherapy regimen for at least four weeks before participating in the trial. Exclusion Criteria: 1. Diagnosis of bipolar I or II disorder, based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria. 2. Current or past substance (\< 3 months) (excluding caffeine or nicotine) or alcohol abuse/dependence, as defined in the DSM-5 criteria. Based on DSM-5 criteria, mild cannabis or alcohol use would be allowed in the past 3 months, moderate to severe would be an exclusion. 3. Current use of illegal substances or cannabis confirmed by urine screening test. 4. Concomitant unstable major medical or neurological disease (e.g., uncontrolled diabetes or renal dysfunction). 5. Organic cause of depressive symptoms (e.g. thyroid dysfunction), ruled out by the treating physician. 6. Acute suicidality or life-threatening due to self-neglect. 7. Are pregnant or breastfeeding, or plan to become pregnant during treatment (pregnancy will be assessed by a urine test). 8. Have a specific contraindication to TMS and/or MRI (e.g., personal history of epilepsy or seizures, metal head implant, pacemaker). 9. Unwilling to maintain the current antidepressant regimen. 10. Taking more than 1 mg/day of lorazepam or equivalent. 11. Any other condition that, in the opinion of the investigators, would impair the participant's ability to complete the study.
Conditions Dementia Caregiver, Depressive Symptoms,...
Phase NA
Enrollment 128
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to assess the efficacy of telephone-coached graphic narrative bibliotherapy in improving dementia caregiver depressive symptoms compared with the booklet group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Telephone coached graphic narrative bibliotherapy — Eight weekly sessions of telephone coached graphic narrative bibliotherapy
  • Other: Control group — Reading educational booklet

Primary Outcomes

  • Changes in depressive symptoms (Pre-intervention, immediately post-intervention, 6 months post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-01
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 128 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Contact Information
Study Contact:
Shanshan Wang
27664696
shan-shan.wang@polyu.edu.hk
The Hong Kong Polytechnic University
Interventions
  • Other: Telephone coached graphic narrative bibliotherapy — Eight weekly sessions of telephone coached graphic narrative bibliotherapy
  • Other: Control group — Reading educational booklet
Study Locations (1 sites)
The Hong Kong Polytechnic University, Hong Kong SAR, Hong Kong
Eligibility Criteria
Inclusion Criteria: * provide unpaid care to a person diagnosed with early to moderate stage dementia; * provide at least 14 hours of care a week for at least 3 months * aged 18 years or above * able to read * have depressive symptoms * use a message application Exclusion Criteria: * with an unstable physical or mental condition * with cognitive impairment * receiving medical, psychological, or psychiatric treatment for depression * have been included in another interventional study
Conditions Hypertension
Phase NA
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

This study evaluates a new digital health program that uses artificial intelligence (AI) to help patients lower their blood pressure through personalized lifestyle recommendations. The program collects information about patients' daily habits and blood pressure readings, then uses AI to suggest lifestyle changes that may work best for each person. The study will measure how well this program works across different groups of patients and aims to improve the program design to make it more effective and easier to use. The program will be offered to diverse patients at UC San Diego Health, including people of different ages, genders, races/ethnicities, and economic backgrounds, as part of their regular healthcare services.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Digital heath tool — Digital health tool of patient-tailored lifestyle recommendations for blood pressure maintenance. Current "simplified" remote patient monitoring program referred to as "P1000." Requires daily blood pressure readings only.
  • Other: Low-intensity recommendation — AI-enhanced lifestyle and health recommendations provided weekly. This requires blood pressure readings, as well as passive readings, (e.g. sleep, movement), and a daily questionnaire.
  • Other: High-intensity recommendation — AI-enhanced lifestyle and health recommendations provided weekly, plus daily reminders. This requires blood pressure readings, as well as passive readings, (e.g. sleep, movement), and a daily questionnaire.

Primary Outcomes

  • Systolic blood pressure measurement (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-10
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Bureau of Economic Research, Inc.
Collaborators: National Institute on Aging (NIA), University of California, San Diego
Principal Investigators:
  • Itzik Fadlon (PRINCIPAL_INVESTIGATOR) - National Bureau of Economic Research, Inc.
  • Ming Tai-Seale (PRINCIPAL_INVESTIGATOR) - University of California, San Diego
Contact Information
Study Contact:
Amanda Walker
617-588-1445
Alw038@health.ucsd.edu
Ross Graham
rograham@health.ucsd.edu
Amanda Walker
617-588-1445
Alw038@health.ucsd.edu
University of California, San Diego
Interventions
  • Other: Digital heath tool — Digital health tool of patient-tailored lifestyle recommendations for blood pressure maintenance. Current "simplified" remote patient monitoring program referred to as "P1000." Requires daily blood pressure readings only.
  • Other: Low-intensity recommendation — AI-enhanced lifestyle and health recommendations provided weekly. This requires blood pressure readings, as well as passive readings, (e.g. sleep, movement), and a daily questionnaire.
  • Other: High-intensity recommendation — AI-enhanced lifestyle and health recommendations provided weekly, plus daily reminders. This requires blood pressure readings, as well as passive readings, (e.g. sleep, movement), and a daily questionnaire.
Study Locations (1 sites)
University of California, San Diego, La Jolla, California 92093 United States
Eligibility Criteria
Inclusion Criteria: * Stage I-II hypertension (average clinical readings of blood pressure over 140/90) * Adequate decisional capacity to make a choice about participating in this research study * Fully ambulatory (not requiring assistive device such as a cane, wheelchair, walker, etc.) Exclusion Criteria: * Pregnancy * Under age 18 years * Institutionalized individuals who are likely to be vulnerable * Dependent on supplemental oxygen
Conditions Periodontal Diseases, Pregnancy Complica...
Phase NA
Enrollment 600
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

Pregnant women are susceptible to develop periodontitis, but these oral health changes related to pregnancy are often neglected. Periodontitis is accompanied by a low-grade systemic inflammation and can be harmful to the general health of the woman, contribute to pre-term birth and adversely influence the future health and metabolism of the offspring. Despite this, studies indicate that 40% of Danish women in childbearing age do not visit a dentist regularly. The PROBE controlled intervention study will investigate the beneficial effect of treatment of periodontal disease during pregnancy on fetal growth, preterm delivery and birth weight.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Periodontal treatment — Periodontal treatment

Primary Outcomes

  • Prevalence of preterm birth (18 months)
  • Prevalence of low birthweight (18 months)
  • Increased risk markers for preeclampsia (18 months)
  • Prevalence of gestational diabetes (18 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-13
Completion: 2026-05
Eligibility
Age: 16 Years – 48 Years
Sex: FEMALE
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital Bispebjerg and Frederiksberg
Principal Investigators:
  • Berit Lilienthal Heitmann, Professor (PRINCIPAL_INVESTIGATOR) - University Hospital Bispebjerg and Frederiksberg
Contact Information
Study Contact:
Karoline Winckler, Phd
38163016
karoline.winckler@regionh.dk
Kathrine Bukkehave, Dentist
5155 9181
kathrine.hansen.bukkehave@regionh.dk
Heidi Fischer, Midwife
59484320
hefi@regionsjaelland.dk
Holbaek Hospital
Interventions
  • Other: Periodontal treatment — Periodontal treatment
Study Locations (3 sites)
Holbaek Hospital, Holbæk, Holbaek 4300 Denmark
Holbæk Hospital, Holbæk, Holbaek 4300 Denmark
Nykøbing Falster Hospital, Nykøbing Falster, Nykøbing Falster 4800 Denmark
Eligibility Criteria
Inclusion Criteria: * Pregnant women who are planned to give birth at either Holbaek or Nykoebing Falster hospital * Pregnant women diagnosed with periodontitis (stage I-III) by the study dentist Exclusion Criteria: * Pregnant women without peridontitis * Pregnant women with less than 20 healthy teeths * Pregnant women with peridontitis and currently receiving treatment for peridontitis * Pregnant women with peridontitis stage IV
Conditions Pulmonary Arterial Hypertension (PAH), L...
Phase Not Applicable
Enrollment 16
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-14
Study Details Design, interventions, and primary outcomes

About This Study

The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung diseases (LFD). Main Objective To demonstrate the ability of XHALIP to improve the prognosis of PAH and LFD by reducing pulmonary fibrosis and vascular remodeling. Key Research Questions Is XHALIP effectively absorbed by pathological lung cells? Does it have a beneficial biological effect on cell proliferation and extracellular matrix deposition? Study Plan Preclinical phase: In vitro tests on cells obtained from patients with PAH and LFD. Absorption and distribution analysis: In vitro lung tissue models to assess drug penetration and effectiveness. Biological activity assessment: Evaluating XHALIP's ability to inhibit epithelial-mesenchymal transition and cell proliferation. Participants Patients aged ≥ 18 years diagnosed with PAH or LFD, either candidates for or recipients of lung transplantation. Biological samples (bronchoalveolar lavage and explanted lung tissues). Methodology Confocal microscopy and flow cytometry to analyze absorption. RT-PCR and Western Blot to assess biological efficacy. Alveolo-capillary models to test drug release and distribution. The study aims to translate preclinical findings into a potential future clinical trial for the development of XHALIP as a novel inhalation-based therapeutic strategy for rare lung diseases.

Design

Study type: Observational Observational model: Other Time perspective: Other

Primary Outcomes

  • Complete synthesis and characterization of XHALIP for in vitro studies. (two years from the enrollment)
  • Complete synthesis and characterization of XHALIP for in vitro studies. (two years from the enrollment)
  • Complete synthesis and characterization of XHALIP for in vitro studies. (two years from the enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-12-04
Completion: 2026-06-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia
Contact Information
Study Contact:
Stefano Ghio, MD
+39 0382503460
s.ghio@smatteo.pv.it
Stefano Ghio, MD
+39 0382503460
s.ghio@smatteo.pv.it
Fondazione IRCCS Policlinico San Matteo
Interventions
N/A
Study Locations (1 sites)
Fondazione IRCCS Policlinico San Matteo, Pavia, Pavia 27100 Italy
Eligibility Criteria
Inclusion Criteria: * Patients aged ≥ 18 years diagnosed with fibrosing lung disease, obliterative bronchiolitis, or PAH, who are candidates for or have undergone lung transplantation. * Obtaining informed consent for all patients enrolled prospectively and all those enrolled retrospectively at their first clinical occurrence at our center. Exclusion Criteria: * Suspected or confirmed diagnosis of pulmonary neoplastic disease.